Byetta Safety Concerns Could Set Roadblocks Ahead For New GLP-1s
This article was originally published in The Pink Sheet Daily
Executive Summary
Amylin/Lilly’s Byetta LAR and Novo Nordisk’s liraglutide could face tougher regulatory scrutiny after cases of pancreatitis are linked to exenatide.
You may also be interested in...
Medco Study Lets Januvia And Byetta Off The Hook For Pancreatitis
Pharmaceutical benefits manager's review of almost 800,000 claims does not show higher risk for these two drugs, despite label warnings.
Medco Study Lets Januvia And Byetta Off The Hook For Pancreatitis
Pharmaceutical benefits manager's review of almost 800,000 claims does not show higher risk for these two drugs, despite label warnings.
Amylin Submits Once-Weekly Byetta After Shedding 200 Sales Reps
Label with expanded language about thyroid cancer risk is expected.